Novartis AG (SWX:NOVN)
Switzerland · Delayed Price · Currency is CHF | Market Cap | 178.66B |
| Revenue (ttm) | 43.89B |
| Net Income (ttm) | 10.86B |
| Shares Out | 1.94B |
| EPS (ttm) | 5.45 |
| PE Ratio | 16.94 |
| Forward PE | 13.35 |
| Dividend | 3.50 (3.79%) |
| Ex-Dividend Date | Mar 11, 2025 |
| Volume | 1,162,016 |
| Average Volume | 2,675,211 |
| Open | 91.73 |
| Previous Close | 92.29 |
| Day's Range | 91.20 - 92.32 |
| 52-Week Range | 81.10 - 102.72 |
| Beta | 0.53 |
| RSI | 33.96 |
| Earnings Date | Jul 17, 2025 |
About Novartis AG
Novartis AG engages in the research, development, manufacture, distribution, marketing, and sale of pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor for the treatment of symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Re... [Read more]
Financial Performance
In 2024, Novartis AG's revenue was $51.72 billion, an increase of 10.85% compared to the previous year's $46.66 billion. Earnings were $11.94 billion, a decrease of -19.59%.
Financial numbers in USD Financial StatementsNews
Novartis AG 2025 Q2 - Results - Earnings Call Presentation
Novartis AG (NVS) Q2 2025 Earnings Call Transcript
Uber & Lucid deal, Alcoa & Novartis CEOs talk earnings
Here is what you may have missed on Market Catalysts for Thursday, July 17. Uber and Lucid are partnering on a new robotaxi service.
Novartis CEO: We're in open discussions with the Trump administration
Novartis CEO Vas Narasimhan said Thursday that the company is in open discussions with the Trump administration over pharmaceutical tariffs, aiming to strike a balance between lowering patient costs a...
Tariffs are an overhang on pharma sector, but we will comeback, says Novartis CEO Vas Narasimhan
Vas Narasimhan, Novartis CEO, joins 'Money Movers' to discuss tariffs on pharmaceuticals, second quarter earnings and outlook on the pharma sector.
Novartis: Q2 Earnings Review - Solid Results Justify All-Time High Share Price
Tariffs are an overhang on pharma sector, but we will comeback, says Novartis CEO Vas Narasimhan
Vas Narasimhan, Novartis CEO, joins 'Money Movers' to discuss tariffs on pharmaceuticals, second quarter earnings and outlook on the pharma sector.
Novartis Launches Buyback of Up to $10 Billion, Lifts Profit Outlook
Novartis raises outlook on strong second-quarter sales
CNBC's Karen Gilchrist weighs in on Novartis' second-quarter earnings and efforts to diversify its drug portfolio beyond its blockbuster Entresto heart failure treatment.
Swiss pharma giant Novartis bets on a breast cancer blockbuster as sales rise
Sales of breast cancer drug Kisqali grew 100% in the U.S. in the three months to June.
Novartis raises outlook on strong second-quarter sales
CNBC's Karen Gilchrist weighs in on Novartis' second-quarter earnings and efforts to diversify its drug portfolio beyond its blockbuster Entresto heart failure treatment.
Novartis Makes A Bearish Move As One Of Its Bread-And-Butter Drugs Misses
Novartis stock fell early Thursday after the drugmaker reported light sales of Cosentyx, one of its biggest moneymakers.
Novartis Trims Operating Income Outlook After Strong Q2 Performance, Initiates $10 Billion Stock Buyback
Swiss pharmaceutical giant Novartis AG (NYSE: NVS) reported second-quarter 2025 earnings on Thursday and raised its full-year earnings forecast. Quarterly sales reached $14.05 billion, almost in line...
Novartis launches up to $10 billion buyback, lifts outlook
Earnings Scheduled For July 17, 2025
Companies Reporting Before The Bell • Taiwan Semiconductor (NYSE: TSM) is estimated to report quarterly earnings at $2.37 per share on revenue of $30.04 billion. • Novartis (NYSE: NVS) is projected ...
Novartis lifts full-year profit forecast, announces $10 billion share buyback
Swiss pharmaceutical giant Novartis has raised its full-year earnings forecast, citing robust revenue growth from key products, including its breast cancer drug Kisqali, during a strong second quarter...
Earnings Snapshot: Novartis International tops Q2 estimates; raises FY25 guidance for core operating income
Novartis Non-GAAP EPS of $2.42 beats by $0.05, revenue of $14.05B in-line; updates FY outllook
Novartis slightly raises 2025 earnings forecast, citing strong Q2
Novartis on Thursday posted a slightly more optimistic full-year earnings forecast, citing the strong growth of drugs such as breast cancer drug Kisqali during the second quarter.
Novartis Appoints Mukul Mehta as Chief Financial Officer, as Harry Kirsch Retires after 22 Years with the Company
Ad hoc announcement pursuant to Art. 53 LR Mukul Mehta, currently Head of Business Planning and Analysis (BPA), Digital Finance and Tax, has been appointed Chief Financial Officer, effective March 16,...
Novartis reports strong Q2 with double-digit sales growth and core margin expansion; raises FY 2025 core operating income guidance
Ad hoc announcement pursuant to Art. 53 LR Q2 net sales grew +11% (cc 1 , +12% USD) with core operating income 1 up +21% (cc, +20% USD) Sales growth driven by continued strong performance from Kisqali...
Novartis fails in bid to block MSN Pharma’s generic Entresto as court denies injunction
Novartis cannot block generic version of Entresto, judge rules
A federal judge rejected Novartis' request for a preliminary injunction to stop MSN Pharmaceuticals from selling a generic version of the blockbuster heart medication Entresto.
Divi’s Laboratories shares fall 3% after MSN wins Entresto patent case
Shares of Divi’s Laboratories fell 3% in early trade after MSN Laboratories secured a win in a key patent litigation case involving Novartis’s blockbuster heart failure drug Entresto (Sacubitril/Valsa...